Inventiva Gains Positive Nod for Lanifibranor Trial
Company Announcements

Inventiva Gains Positive Nod for Lanifibranor Trial

Inventiva (IVA) has released an update.

Inventiva has announced a positive recommendation from the Data Monitoring Committee for its NATiV3 Phase 3 clinical trial of lanifibranor, highlighting the drug’s promising safety profile in treating MASH. With over 1000 patients involved, this endorsement reinforces lanifibranor as a potential breakthrough in addressing metabolic liver diseases. Investors and market analysts may view this as a significant step forward for Inventiva’s clinical and commercial prospects.

For further insights into IVA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyInventiva announces DMC recommendation to continue NATiV3 trial as is
TipRanks Auto-Generated NewsdeskInventiva’s 2024 Interim Financial Highlights and Prospects
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App